Header

UZH-Logo

Maintenance Infos

Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data


Barthelmes, D; Walton, R; Campain, A E; Simpson, J M; Arnold, J J; McAllister, I L; Guymer, R H; Hunyor, R H; Essex, R W; Morlet, N; Gillies, M C (2015). Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data. The British Journal of Ophthalmology, 99(3):359-364.

Abstract

AIM: To describe outcomes of eyes with wet age-related macular degeneration (AMD) subdivided by lesion activity in a large multicentre cohort study.
METHODS: Treatment-naive eyes with subfoveal choroidal neovascularisation receiving antivascular endothelial growth factor therapy enrolled in the Fight Retinal Blindness observational study were included. Lesions were graded at each visit as active if there was intraretinal or subretinal fluid attributable to leak from choroidal neovascularisation lesion or fresh haemorrhage. Eyes were divided into four groups; based on the proportion of visits, each eye was graded as active during the first 12 months of treatment (persistent, high, moderate and low activity).
RESULTS: 655 eyes were included. Similar mean visual acuity changes compared with baseline were observed in all four groups at 12 months (+6.8, +8.3, +6.2 and +5.5 letters for the low, moderate, high and persistent groups, respectively; p<0.001 for each group). The mean number of injections given increased only modestly in groups with more active lesions (7.6, 7.9, 8.4 and 8.3, respectively, p=0.015). Occult and minimally classic lesions were more frequent in the more active groups (p=0.024).
CONCLUSIONS: Persistent activity of neovascular lesions during 12 months after starting intravitreal therapy was not associated with worse visual outcomes in this observational study of AMD.

Abstract

AIM: To describe outcomes of eyes with wet age-related macular degeneration (AMD) subdivided by lesion activity in a large multicentre cohort study.
METHODS: Treatment-naive eyes with subfoveal choroidal neovascularisation receiving antivascular endothelial growth factor therapy enrolled in the Fight Retinal Blindness observational study were included. Lesions were graded at each visit as active if there was intraretinal or subretinal fluid attributable to leak from choroidal neovascularisation lesion or fresh haemorrhage. Eyes were divided into four groups; based on the proportion of visits, each eye was graded as active during the first 12 months of treatment (persistent, high, moderate and low activity).
RESULTS: 655 eyes were included. Similar mean visual acuity changes compared with baseline were observed in all four groups at 12 months (+6.8, +8.3, +6.2 and +5.5 letters for the low, moderate, high and persistent groups, respectively; p<0.001 for each group). The mean number of injections given increased only modestly in groups with more active lesions (7.6, 7.9, 8.4 and 8.3, respectively, p=0.015). Occult and minimally classic lesions were more frequent in the more active groups (p=0.024).
CONCLUSIONS: Persistent activity of neovascular lesions during 12 months after starting intravitreal therapy was not associated with worse visual outcomes in this observational study of AMD.

Statistics

Citations

Dimensions.ai Metrics
5 citations in Web of Science®
6 citations in Scopus®
6 citations in Microsoft Academic
Google Scholar™

Altmetrics

Downloads

2 downloads since deposited on 09 Dec 2014
0 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Ophthalmology Clinic
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:March 2015
Deposited On:09 Dec 2014 15:48
Last Modified:14 Feb 2018 08:44
Publisher:BMJ Publishing Group
ISSN:0007-1161
OA Status:Closed
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1136/bjophthalmol-2014-305514
PubMed ID:25249615

Download